Cinclus Pharma Holding AB CINPAS
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Shares Outstanding
- 46.54M
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Cinclus Pharma Holding AB is a Swedish clinical-stage pharmaceutical company focused on developing small-molecule treatments for gastric acid-related diseases. Its candidate, linaprazan glurate, is being developed for the treatment of severe gastroesophageal reflux disease, including erosive forms. The company is also developing a dual therapy treatment with an antibiotic targeting Helicobacter pylori, a bacterium found in the gastric and duodenal mucosa. Its primary target population consists of patients with severe erosive gastroesophageal reflux disease, where current treatment options are limited. It operates in Switzerland, Sweden, and the Czech Republic, with the majority of revenue from the Czech Republic.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Value
- Total Number of Employees
- 17
- Website
- https://www.cincluspharma.com
Valuation
|
Metric
|
CINPAS
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
CINPAS
|
|---|---|
Quick Ratio | 2.30 |
Current Ratio | 2.30 |
Interest Coverage | — |
Quick Ratio
CINPAS
Profitability
|
Metric
|
CINPAS
|
|---|---|
Return on Assets (Normalized) | −49.71% |
Return on Equity (Normalized) | −76.30% |
Return on Invested Capital (Normalized) | −76.05% |
Return on Assets
CINPAS
Drug Manufacturers - Specialty & Generic Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Merck KGaA ADR
MKKGY
| LOCK|>D<&kQsX | LOCK|?@?d | $66B | |||
| Teva Pharmaceutical Industries Ltd
TEVA
| LOCK|Lb>R>Ft | LOCK|<>!bd | $45B | |||
| Haleon PLC ADR
HLN
| LOCK|g$<%b$& | LOCK|b< | $40B | |||
| Zoetis Inc Class A
ZTS
| LOCK|W#@KLGvQ | LOCK|Tx$ | $30B | |||
| Viatris Inc
VTRS
| LOCK|T$#&$Qk | LOCK|rK | $20B | |||
| Elanco Animal Health Inc
ELAN
| LOCK|N@ | LOCK|ph | $11B | |||
| Dr Reddy's Laboratories Ltd ADR
RDY
| LOCK|$yZXT! | LOCK|t@ | $10B | |||
| Hims & Hers Health Inc Ordinary Shares - Class A
HIMS
| LOCK|<##zj@ | LOCK|?q! | $7B | |||
| Prestige Consumer Healthcare Inc
PBH
| LOCK|^psM?> | LOCK|wLV&& | $2B | |||
| Perrigo Co PLC
PRGO
| LOCK|Lp#y@N& | LOCK|#%p | $2B |
United States